The Case for Better Access to Islet Cell Transplantation

For people living with type 1 diabetes, islet cell transplantation represents one of the most promising avenues toward reduced insulin dependence and improved quality of life. Despite decades of clinical progress and growing evidence of its benefits, access to this procedure remains frustratingly limited. Patients face a tangled web of insurance denials, regional shortages of specialized transplant centers, complex regulatory hurdles, and a general lack of awareness among both the public and many healthcare professionals. Advocacy is not a luxury—it is a necessity. This expanded guide offers a detailed roadmap for patients, families, clinicians, and community organizers who want to push for meaningful change in how islet cell transplantation services are funded, regulated, and delivered.

Understanding Islet Cell Transplantation: A Primer for Advocates

Islet cell transplantation is a minimally invasive procedure in which insulin-producing islet cells are isolated from a deceased donor’s pancreas and infused into the liver of a person with type 1 diabetes. Once engrafted, these cells begin to produce insulin in response to blood glucose levels, often eliminating severe hypoglycemia and, in many cases, reducing or even removing the need for exogenous insulin injections.

Who Is Eligible?

Candidates are typically adults with type 1 diabetes who experience recurrent severe hypoglycemia (hypoglycemia unawareness) or blood glucose lability that persists despite optimal medical management. The procedure is generally not offered to children or to individuals with significant kidney disease, though research is ongoing to expand eligibility.

What Are the Outcomes?

According to data from the Collaborative Islet Transplant Registry (CITR), about 50–70% of recipients achieve insulin independence at one year post-transplant, and many maintain some degree of graft function for five years or longer. The most significant benefit is the near-elimination of severe hypoglycemic episodes, which dramatically reduces the risk of accidents, coma, and death. However, recipients must take lifelong immunosuppressive drugs, which carry their own risks—a trade-off that underscores the need for continued research into safer protocols.

Why Is Access So Limited?

Islet transplantation is approved as a standard therapy in much of Europe, Australia, and Canada. In the United States, it is still classified as an investigational procedure by many insurers, including Medicare, despite being performed with high success rates at specialized centers. This classification creates a circular barrier: without insurance coverage, few patients can afford the costs (often exceeding $100,000 per procedure), and without a large patient volume, centers struggle to demonstrate the real-world data needed to change the classification. Other barriers include a limited number of experienced transplant centers, organ shortage, and inconsistent federal funding for research and infrastructure.

Barriers to Access: A Deeper Look

To advocate effectively, you must first understand the specific obstacles that limit access. These barriers operate at multiple levels—patient, provider, payer, and policy.

Insurance and Payer Policies

The single greatest hurdle for most patients is insurance denial. Many private insurers, as well as Medicare and Medicaid, classify islet transplantation as experimental. Even when a policy does not explicitly exclude it, prior authorization requirements, copays, and the need for out-of-network providers can make the process prohibitively difficult. For example, a 2023 survey by the American Diabetes Association found that fewer than 5% of U.S. health plans listed islet transplantation as a covered benefit for type 1 diabetes. Advocacy must target both regulatory agencies and individual insurance companies to push for reclassification.

Geographic and Institutional Concentration

In the United States, fewer than 15 centers perform islet transplantation on a regular basis, and most are located in major academic medical centers on the coasts. Patients in rural states, the Midwest, or the South often face travel distances of several hundred miles and must relocate temporarily for the procedure and follow-up care. This creates an equity gap: wealthier patients with flexible schedules are far more likely to access treatment than low-income individuals or those with caregiving responsibilities.

Regulatory and Funding Barriers

In many countries, the regulatory pathway for cellular therapies is still evolving. The U.S. Food and Drug Administration (FDA) regulates islet cells as a biological product, and the process to obtain a Biologics License Application (BLA) approval has been slow. This regulatory uncertainty discourages investment and keeps the procedure in a limbo state—neither fully approved nor officially abandoned. Researchers and advocacy groups must apply constant pressure to expedite review and create a clear framework for coverage.

Lack of Awareness Among Clinicians

Many endocrinologists and primary care providers simply do not know about the current state of islet transplantation. They may be unaware that it is an option for patients who are not candidates for whole-pancreas transplant, or they may underestimate its efficacy. This knowledge gap leads to under-referral and delays in patients even learning about the procedure.

Steps to Advocate for Better Access: An Expanded Action Plan

The following five pillars form the foundation of an effective advocacy campaign. Each section includes specific, actionable tactics.

1. Educate Yourself and Others

Begin by becoming an expert on the science, the policy, and the personal realities of islet transplantation. Arm yourself with accurate data from sources such as the Collaborative Islet Transplant Registry (CITR) and the American Diabetes Association.

  • Read the key studies: Review landmark papers on long-term outcomes, immunosuppression, and cost-effectiveness.
  • Understand your local environment: Identify which insurers cover islet transplantation in your state or region, and which do not.
  • Create simple educational materials: One-page handouts with bullet points and infographics are highly effective for sharing with providers, legislators, and community groups.
  • Host a webinar or workshop: Partner with a local diabetes support group or a university medical center to present an overview of the procedure and the advocacy needs.

2. Engage with Policymakers

Systemic change requires the attention of legislators, regulators, and public health officials. These individuals respond best to personal stories backed by data.

  • Schedule meetings with your representatives: Write a letter or call the local office of your state senator or representative. Request a brief in-person or virtual meeting to discuss the need for islet transplantation coverage. Bring a patient story and one or two key statistics.
  • Testify at public hearings: Many state insurance departments hold public hearings on mandated benefits. If your state is considering a diabetes-related bill, offer to testify on the importance of including islet transplantation.
  • Encourage legislative action: Advocate for bills that would mandate insurance coverage for islet transplantation, or that would allocate state funds for a demonstration project at a regional hospital.
  • Collaborate with national organizations: Groups like the JDRF Advocacy Network have templates and trained volunteers who can help you approach state and federal lawmakers.

3. Partner with Healthcare Providers

Change from within the medical system is critical. Clinicians can become powerful allies if they understand the value of islet transplantation.

  • Identify a champion at your local hospital or academic medical center—ideally a transplant surgeon, an endocrinologist, or a clinical research coordinator who is willing to advocate internally.
  • Host a grand rounds presentation: Work with that champion to schedule a presentation about islet transplantation for the department of endocrinology or surgery. Provide the most recent data and patient testimonials.
  • Improve referral pathways: Advocate for your hospital to establish a formal referral algorithm for patients with severe hypoglycemia, including a consultation with an islet transplant team.
  • Educate primary care providers: Family doctors and internists often see patients with type 1 diabetes for routine care. A brief informational email or flyer can raise awareness and prompt referrals.

4. Build Community Support

No advocacy effort succeeds in isolation. Building a visible, vocal community amplifies your message and demonstrates widespread need.

  • Share patient stories: Collect written or video testimonials from individuals whose lives have been transformed by islet transplantation. Focus on the reduction in severe hypoglycemia and the regained quality of life. Obtain written permission before using any story publicly.
  • Create a support group: Many patients feel isolated by their condition. A local or online support group for candidates, recipients, and families provides emotional support and a ready-made advocacy base.
  • Organize awareness events: Hold a community walk, a health fair booth, or a virtual town hall. Use events to gather petition signatures for insurer coverage or legislative support.
  • Use social media strategically: Create a dedicated Facebook group or Twitter/X account for your advocacy campaign. Share updates, data, and stories. Use hashtags like #IsletAccess, #T1DAdvocacy, or #CoverIsletTransplants.

5. Advocate for Insurance Coverage

This is often the hardest and most direct front in the fight. It requires persistence and knowledge of the appeals process.

  • Learn the appeals process: Understand your insurer’s internal appeals and external review (independent medical review) procedures. Keep detailed records of all communications.
  • Submit a formal request for coverage: Work with your transplant center’s insurance liaison to submit a “medical necessity” letter. Include published studies, your personal medical history, and a letter of support from your physician.
  • Engage your employer’s HR department: If you have employer-based insurance, ask your benefits manager to consider adding islet transplantation as a covered benefit. Employee testimonials can be very persuasive.
  • Consider state-based advocacy: In some states, mandated benefit laws require insurers to cover specific treatments for diabetes. Research whether your state has such a law and whether it could be expanded.

Effective Advocacy Strategies: Lessons from Successful Campaigns

Advocates around the world have already achieved meaningful improvements in islet transplantation access. Studying these successes can inform your own strategy.

Case Study: Alberta, Canada

In 2018, a coalition of patients, transplant clinicians, and diabetes organizations in Alberta successfully lobbied the provincial health ministry to fund islet transplantation as a standard therapy. Key tactics included presenting a cost-effectiveness analysis showing that the procedure saved the healthcare system money over ten years compared to managing severe hypoglycemia, and personal testimony from a young mother whose life changed after transplantation. Today, the Islet Transplant Program at the University of Alberta serves as a model for publicly funded access.

Case Study: The UK’s NHS National Commissioning

The UK’s National Health Service (NHS) began commissioning islet transplantation as a specialized service in 2008. The advocacy campaign that led to this decision involved coordinated letters from diabetologists, a parliamentary inquiry, and a strong patient advocacy group. The NHS now operates a hub-and-spoke model, with six centers serving the entire country. This case demonstrates that persistent, professional advocacy can secure national-level coverage.

Using Data and Personal Stories Together

Abstract statistics can be ignored; a face and a story are harder to forget. Effective advocacy combines both. For example, when presenting to an insurance committee, show a graph of reduced hypoglycemia rates followed by a two-minute video of a patient talking about being able to drive safely again. Pairing the objective with the subjective creates a powerful emotional and rational argument.

Leveraging the Media

Local newspapers, radio stations, and specialized health blogs are often looking for human-interest stories. Pitch your story or the story of someone you know. Frame it around a current issue—such as rising insulin costs or gaps in diabetes care—to make it newsworthy. A single article or segment can reach thousands of people, including policymakers and potential allies.

Overcoming Common Obstacles in Advocacy

Even with a solid plan, you will face pushbacks. Here are ways to handle them.

“The procedure is still experimental.”

Counter this with the facts: Islet transplantation is approved as standard therapy in Canada, the UK, and many European countries. The U.S. Centers for Medicare & Medicaid Services (CMS) has not yet issued a national coverage determination, but regional Medicare administrative contractors have begun to cover it on a case-by-case basis. Point out that the FDA has designated it as a breakthrough therapy, and that long-term registry data show consistent safety and efficacy.

“It’s too expensive.”

Acknowledge the upfront cost but present the full economic picture. A 2021 study in Diabetes Care estimated that islet transplantation reduces the lifetime healthcare costs of patients with severe hypoglycemia by an average of $90,000 per patient, due to fewer emergency room visits, fewer paramedic call-outs, and reduced insulin use. In the long run, it is cost-effective or even cost-saving.

“We don’t have enough organs.”

Shortage of donor pancreata is real, but improved access would incentivize better organ allocation and increase public willingness to donate. Additionally, research into stem-cell-derived islets (encapsulation and gene editing) promises an unlimited supply in the future. Advocating for better access today also creates the infrastructure needed for tomorrow’s therapies.

Building a Coalition: Who Else Should Be at the Table?

Effective advocacy is rarely done alone. Consider building a coalition that includes:

  • Diabetes patient organizations (e.g., JDRF, Beyond Type 1, the American Diabetes Association)
  • Transplant recipient groups (e.g., the Islet Transplant Advocates Facebook group)
  • Medical professional societies (e.g., The Endocrine Society, American Society of Transplant Surgeons)
  • Bioethics and health equity organizations (to emphasize the justice issues when only the wealthy can access treatment)
  • State and local health departments (who may be willing to fund pilot programs)

Conclusion: The Moment Is Now

Islet cell transplantation has moved beyond the experimental stage. It is a proven, life-changing therapy that remains out of reach for the vast majority of people who need it. The barriers are not primarily scientific or medical—they are political, financial, and organizational. That means they can be changed through focused, persistent advocacy. Whether you are a patient, a family member, a clinician, or a policy enthusiast, you have a role to play. Educate yourself, build your network, tell your story, and demand that insurers and governments treat islet transplantation not as an elective luxury but as a standard of care for those with severe type 1 diabetes. The next decade of diabetes care will be shaped by the advocacy work done today. Be part of that change.